Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/3/2024 | $40.00 | Buy | Jefferies |
| 1/31/2024 | $67.00 | Outperform | BMO Capital Markets |
| 5/8/2023 | $20.00 | Overweight | Morgan Stanley |
| 12/9/2022 | $18.00 | Equal-Weight | Morgan Stanley |
| 3/31/2022 | $33.00 | Buy | Chardan Capital Markets |
Silence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today announced that management will present company overviews at the following conferences: Morgan Stanley Global Healthcare Conference on Thursday, September 5, 2024 at 5:35pm ET HC Wainwright Global Investment Conference on Tuesday, September 10, 2024 at 11:30am ET Cantor Global Healthcare Conference on Tuesday, September 17, 2024 at 10:20am ET Chardan Genetic Medicines Conference on Monday, September 30, 2024 at 9:00am ET A live audio webcast of each pr
Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today reported its financial results for the second quarter ended June 30, 2024 and reviewed recent business highlights. "The first half of this year has been marked by strong execution across Silence, including outstanding clinical results in both our wholly owned clinical programs and advancing our first partnered program into the clinic under our AstraZeneca collaboration," said Craig Tooman, President and Chief Executive Officer at Silence. "Silence's siRNA technolo
Divesiran eliminated the need for phlebotomy in all well-controlled patients following infrequent dosing and was well tolerated Data support advancing divesiran into Phase 2 Company to host conference call today at 8:30am Eastern Time Silence Therapeutics plc ("Silence" or the "Company"), (NASDAQ:SLN), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today announced positive results from the ongoing SANRECO Phase 1 repeat dose study of divesiran (SLN124), a siRNA (short interfering RNA) targeting TMPRSS6, in patients with polycythemia vera (PV). "With today's very exciting PV da
Silence Therapeutics plc (NASDAQ:SLN) ("Silence" or the "Company"), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today announced that Alistair Gray, who has served as an independent member of Silence's Board of Directors (the "Board") since 2015, informed the Company that he will retire from the Board, effective May 1, 2024. Iain Ross, Silence's Chairman of the Board, commented, "Alistair has made significant contributions to the Board and the Company over the past nine years. During his time on the Board, the Company has transitioned into a global player focused on the developmen
Dr. Romano will succeed Dr. Giles Campion, CMO and Head of R&D, following his retirement by year-end Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today announced the appointment of Steven Romano, MD, as incoming Chief Medical Officer and Head of Research and Development. Dr. Romano will join Silence on April 1, 2023, and work alongside Giles Campion, MD, current CMO and Head of R&D at Silence, to ensure an efficient and smooth transition for Dr. Campion's retirement by year-end. Dr. Romano has served as non-execut
Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today announced the appointment of J.P. Gabriel as Chief Technical Operations Officer following the retirement of Jørgen Wittendorff, SVP, Technical Operations. In this role, J.P. is responsible for Manufacturing, Process and Analytical Development and Supply Chain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230206005194/en/J.P. Gabriel, Chief Technical Operations Officer, Silence Therapeutics plc. (Photo:
Jefferies initiated coverage of Silence Therapeutics with a rating of Buy and set a new price target of $40.00
BMO Capital Markets initiated coverage of Silence Therapeutics with a rating of Outperform and set a new price target of $67.00
Morgan Stanley initiated coverage of Silence Therapeutics with a rating of Overweight and set a new price target of $20.00
F-3ASR - Silence Therapeutics plc (0001479615) (Filer)
6-K - Silence Therapeutics plc (0001479615) (Filer)
6-K - Silence Therapeutics plc (0001479615) (Filer)
Divesiran eliminated the need for phlebotomy in all well-controlled patients following infrequent dosing and was well tolerated Data support advancing divesiran into Phase 2 Company to host conference call today at 8:30am Eastern Time Silence Therapeutics plc ("Silence" or the "Company"), (NASDAQ:SLN), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today announced positive results from the ongoing SANRECO Phase 1 repeat dose study of divesiran (SLN124), a siRNA (short interfering RNA) targeting TMPRSS6, in patients with polycythemia vera (PV). "With today's very exciting PV da
Silence also announced positive topline 36-week data from ongoing phase 2 study of zerlasiran in patients with high lipoprotein(a) Company to host conference call and webcast today at 8 a.m. EDT / 12 p.m. GMT Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today reported its financial results for the full year ended December 31, 2023, and reviewed recent business highlights. "2023 was a year of strong execution across Silence as we advanced our proprietary pipeline in the clinic," said Craig Tooman, President and
Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today announced that the Company will release its financial and business results for the fourth quarter and full year ended December 31, 2023, on Wednesday, March 13, 2024. Management will host a conference call at 8:00 a.m. EDT / 12:00 p.m. GMT that day to discuss the Company's financial results and provide a general business update. The conference call will be webcast live and available on the Investors section of the Silence website at www.silence-therapeutics.com. T
SC 13G/A - Silence Therapeutics plc (0001479615) (Subject)
SC 13D/A - Silence Therapeutics plc (0001479615) (Subject)
SC 13G/A - Silence Therapeutics plc (0001479615) (Subject)
Morgan Stanley analyst Michael Ulz maintains Silence Therapeutics (NASDAQ:SLN) with a Overweight and raises the price target from $45 to $49.
Chardan Capital analyst Keay Nakae maintains Silence Therapeutics (NASDAQ:SLN) with a Buy and raises the price target from $42 to $55.
HC Wainwright & Co. analyst Patrick Trucchio reiterates Silence Therapeutics (NASDAQ:SLN) with a Buy and maintains $75 price target.